Clinical Trials Logo

Rosacea clinical trials

View clinical trials related to Rosacea.

Filter by:

NCT ID: NCT01451619 Completed - Rosacea Clinical Trials

A Study of Laropiprant (MK-0524) in Participants With Moderate to Severe Erythematotelangiectatic Rosacea (MK-0524-155)

Start date: November 2011
Phase: Phase 1
Study type: Interventional

This study will assess the effect of MK-0524 relative to placebo, on signs and symptoms of rosacea and to determine the safety and tolerability profile of MK-0524 in participants with rosacea.

NCT ID: NCT01449591 Completed - Clinical trials for Erythemato-telangiectatic Rosacea

Safety, Tolerability and Efficacy of BFH772 in Rosacea Patients

Start date: September 2011
Phase: Phase 2
Study type: Interventional

This study will evaluate the safety, tolerability and efficacy of BFH772 after 12 weeks of treatment as compared to an active control and vehicle in patients with erythemato-telangiectatic rosacea.

NCT ID: NCT01426269 Completed - Rosacea Clinical Trials

Evaluation of Relapse, Efficacy and Safety of Long-term Treatment With Oracea® vs Placebo

Start date: September 2011
Phase: Phase 4
Study type: Interventional

The purpose of this study is to assess relapse, efficacy and safety in subjects with rosacea during long-term treatment with either Oracea® or placebo, after an initial 12-week regimen of Oracea® and MetroGel® 1%.

NCT ID: NCT01398280 Completed - Rosacea Clinical Trials

Effects of Aminocaproic Acid (ACA) on Rosacea-specific Inflammation

ACA
Start date: July 2011
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to determine the effect of topical aminocaproic acid on the immune system by assessing the levels of antimicrobial peptides in the skin of patients with rosacea. It is hypothesized that aminocaproic acid applied topically will alter the body's immune system in patients with rosacea by inhibiting activation of antimicrobial peptides.

NCT ID: NCT01359228 Withdrawn - Rosacea Clinical Trials

Rifaximin Treatment of Papulopustular Rosacea

Start date: April 2013
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the effects of rifaximin on skin symptoms in patients with rosacea by double-blinded, placebo-controlled, crossover study.

NCT ID: NCT01355471 Completed - Rosacea Clinical Trials

Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea

Start date: May 2011
Phase: Phase 3
Study type: Interventional

This is a Phase 3 efficacy and safety study of CD07805/47 topical gel in subjects with facial erythema associated with rosacea. The study hypothesis is that CD07805/47 gel, applied topically once daily is more efficacious than vehicle and provides an acceptable safety profile in the treatment of facial erythema associated with rosacea.

NCT ID: NCT01355458 Completed - Rosacea Clinical Trials

Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea

Start date: May 2011
Phase: Phase 3
Study type: Interventional

Phase 3 efficacy and safety study of CD07805/47 topical gel in subjects with facial erythema associated with rosacea. The study hypothesis is that CD07805/47 gel, applied topically once daily is more efficacious than vehicle and provides an acceptable safety profile in the treatment of facial erythema associated with rosacea.

NCT ID: NCT01318733 Completed - Rosacea Clinical Trials

Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea

Start date: March 2011
Phase: Phase 3
Study type: Interventional

A long-term, open-label, non-comparative safety and efficacy study of CD07805/47 gel 0.5% once daily in subjects with moderate to severe facial erythema associated with rosacea.

NCT ID: NCT01308619 Completed - Rosacea Clinical Trials

Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo

Start date: April 2011
Phase: Phase 4
Study type: Interventional

The objective of this study is to determine the clinical effects of doxycycline 40 mg (30 mg immediate release and 10 mg delayed release beads) capsules (Oracea®) as compared to placebo in the skin of adults with papulopustular rosacea and to identify a correlation, if any, with rosacea-related inflammatory markers.

NCT ID: NCT01257919 Completed - Clinical trials for Papulopustular Rosacea

Safety and Pharmacokinetics of Azelaic Acid Foam, 15% in Papulopustular Rosacea

Start date: January 2011
Phase: Phase 1
Study type: Interventional

Assessment of pharmacokinetics of Azelaic Acid Foam after repeated skin application and in comparison to Azelaic Acid gel. Assessment of safety after repeated skin application.